A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors
Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Putnam, K. G. [verfasserIn] Bohn, R. L. [verfasserIn] Ewenstein, B. M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2005 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2005 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Haemophilia - Oxford [u.a.] : Wiley-Blackwell, 1995, 11(2005), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:11 ; year:2005 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1365-2516.2005.01098.x |
|---|
| Katalog-ID: |
NLEJ242799248 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242799248 | ||
| 003 | DE-627 | ||
| 005 | 20210707164232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1365-2516.2005.01098.x |2 doi | |
| 035 | |a (DE-627)NLEJ242799248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Putnam, K. G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. | ||
| 533 | |d 2005 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2005|||||||||| | ||
| 650 | 4 | |a activated prothrombin complex complexes | |
| 700 | 1 | |a Bohn, R. L. |e verfasserin |4 aut | |
| 700 | 1 | |a Ewenstein, B. M. |e verfasserin |4 aut | |
| 700 | 1 | |a Winkelmayer, W. C. |4 oth | |
| 700 | 1 | |a Avorn, J. |4 oth | |
| 773 | 0 | 8 | |i In |t Haemophilia |d Oxford [u.a.] : Wiley-Blackwell, 1995 |g 11(2005), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243925867 |w (DE-600)2006344-1 |x 1365-2516 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2005 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2005 |e 3 |h 0 | ||
| author_variant |
k g p kg kgp r l b rl rlb b m e bm bme |
|---|---|
| matchkey_str |
article:13652516:2005----::csmnmztomdloteramnomnrleigpsdsnainsihamp |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1111/j.1365-2516.2005.01098.x doi (DE-627)NLEJ242799248 DE-627 ger DE-627 rakwb Putnam, K. G. verfasserin aut A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Oxford, UK Blackwell Science Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| activated prothrombin complex complexes Bohn, R. L. verfasserin aut Ewenstein, B. M. verfasserin aut Winkelmayer, W. C. oth Avorn, J. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| spelling |
10.1111/j.1365-2516.2005.01098.x doi (DE-627)NLEJ242799248 DE-627 ger DE-627 rakwb Putnam, K. G. verfasserin aut A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Oxford, UK Blackwell Science Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| activated prothrombin complex complexes Bohn, R. L. verfasserin aut Ewenstein, B. M. verfasserin aut Winkelmayer, W. C. oth Avorn, J. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfields_unstemmed |
10.1111/j.1365-2516.2005.01098.x doi (DE-627)NLEJ242799248 DE-627 ger DE-627 rakwb Putnam, K. G. verfasserin aut A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Oxford, UK Blackwell Science Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| activated prothrombin complex complexes Bohn, R. L. verfasserin aut Ewenstein, B. M. verfasserin aut Winkelmayer, W. C. oth Avorn, J. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfieldsGer |
10.1111/j.1365-2516.2005.01098.x doi (DE-627)NLEJ242799248 DE-627 ger DE-627 rakwb Putnam, K. G. verfasserin aut A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Oxford, UK Blackwell Science Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| activated prothrombin complex complexes Bohn, R. L. verfasserin aut Ewenstein, B. M. verfasserin aut Winkelmayer, W. C. oth Avorn, J. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| allfieldsSound |
10.1111/j.1365-2516.2005.01098.x doi (DE-627)NLEJ242799248 DE-627 ger DE-627 rakwb Putnam, K. G. verfasserin aut A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors Oxford, UK Blackwell Science Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| activated prothrombin complex complexes Bohn, R. L. verfasserin aut Ewenstein, B. M. verfasserin aut Winkelmayer, W. C. oth Avorn, J. oth In Haemophilia Oxford [u.a.] : Wiley-Blackwell, 1995 11(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243925867 (DE-600)2006344-1 1365-2516 nnns volume:11 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 11 2005 3 0 |
| source |
In Haemophilia 11(2005), 3, Seite 0 volume:11 year:2005 number:3 pages:0 |
| sourceStr |
In Haemophilia 11(2005), 3, Seite 0 volume:11 year:2005 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
activated prothrombin complex complexes |
| isfreeaccess_bool |
false |
| container_title |
Haemophilia |
| authorswithroles_txt_mv |
Putnam, K. G. @@aut@@ Bohn, R. L. @@aut@@ Ewenstein, B. M. @@aut@@ Winkelmayer, W. C. @@oth@@ Avorn, J. @@oth@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243925867 |
| id |
NLEJ242799248 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242799248</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707164232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2516.2005.01098.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242799248</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Putnam, K. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">activated prothrombin complex complexes</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bohn, R. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ewenstein, B. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winkelmayer, W. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Avorn, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Haemophilia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1995</subfield><subfield code="g">11(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925867</subfield><subfield code="w">(DE-600)2006344-1</subfield><subfield code="x">1365-2516</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Putnam, K. G. |
| spellingShingle |
Putnam, K. G. misc activated prothrombin complex complexes A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| authorStr |
Putnam, K. G. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243925867 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2516 |
| topic_title |
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors activated prothrombin complex complexes |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc activated prothrombin complex complexes |
| topic_unstemmed |
misc activated prothrombin complex complexes |
| topic_browse |
misc activated prothrombin complex complexes |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
w c w wc wcw j a ja |
| hierarchy_parent_title |
Haemophilia |
| hierarchy_parent_id |
NLEJ243925867 |
| hierarchy_top_title |
Haemophilia |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243925867 (DE-600)2006344-1 |
| title |
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| ctrlnum |
(DE-627)NLEJ242799248 |
| title_full |
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| author_sort |
Putnam, K. G. |
| journal |
Haemophilia |
| journalStr |
Haemophilia |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Putnam, K. G. Bohn, R. L. Ewenstein, B. M. |
| container_volume |
11 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Putnam, K. G. |
| doi_str_mv |
10.1111/j.1365-2516.2005.01098.x |
| author2-role |
verfasserin |
| title_sort |
a cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia a and high-titre inhibitors |
| title_auth |
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| abstract |
Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. |
| abstractGer |
Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. |
| abstract_unstemmed |
Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors |
| url |
http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x |
| remote_bool |
true |
| author2 |
Bohn, R. L. Ewenstein, B. M. Winkelmayer, W. C. Avorn, J. |
| author2Str |
Bohn, R. L. Ewenstein, B. M. Winkelmayer, W. C. Avorn, J. |
| ppnlink |
NLEJ243925867 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1111/j.1365-2516.2005.01098.x |
| up_date |
2024-07-06T03:14:12.261Z |
| _version_ |
1803797819304181760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242799248</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707164232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2516.2005.01098.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242799248</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Putnam, K. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary. Treatment of acute bleeding episodes in patients with haemophilia A and inhibitory antibodies to factor VIII (FVIII) most often involves the use of bypassing haemostatic agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa). We constructed a cost minimization model to compare the costs of initial treatment with aPCC vs. rFVIIa in the home treatment of minor bleeding episodes. We developed a clinical scenario describing such a case and presented it to a panel of US haemophilia specialists. For each product class, we asked panellists to provide dosing regimens required to achieve complete resolution of a minor haemarthrosis in a child with high-titre inhibitors, and for the probabilities of success at two time points (8–12 and 24 h). Consensus among the panellists was refined by a second round of the process, and the median values resulting were used as inputs to a decision analysis model. Sensitivity analyses were conducted to determine threshold values for key variables. The base case model found that initial treatment with aPCC would result in a mean cost per episode of $21 000, compared with $33 400 for initial treatment with rFVIIa. Sensitivity analyses over a range of clinically plausible values for cost, dosing, and efficacy did not change the selection of aPCC as the dominant strategy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">activated prothrombin complex complexes</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bohn, R. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ewenstein, B. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winkelmayer, W. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Avorn, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Haemophilia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1995</subfield><subfield code="g">11(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925867</subfield><subfield code="w">(DE-600)2006344-1</subfield><subfield code="x">1365-2516</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2516.2005.01098.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3979836 |